Clinical stage biopharmaceutical company focusing on developing novel treatment therapies for neurological disorders and management of mental illness GH Research PLC made its debut on the Nasdaq stock exchange market.
In the initial public offering held on June 2, the company floated 10 million shares with each shares going for a $16 in the IPO. The company fetched approximately $160 million from this IPO.
Shares of the company will be trading on Nasdaq under the ticker symbol ‘GHRS’.
Dublin based GH Research is currently studying the potential of 5-MeO-DMT in treatment of neurological disorders and psychiatric. Not long ago, the company unveiled GH001, an inhalable 5-MeO-DMT analog, which is under study for the treatment of chronic depression, along with proprietary therapies.
GH Research concluded its phase one clinical study on GH001 late last year after using healthy volunteers in the study which was testing for efficacy and safety.